Research is what will lead us to a cure
Treatment outcomes for children with cancer have made tremendous improvements in the past 50 years.
Certain childhood cancers, such as standard risk leukemia and a kidney tumor called Wilms' tumor, now have treatment success rates of more than 90%. But despite great advances in how childhood cancer is treated, the reality is one in five children with cancer will still die of their disease within 5 years.
"Research into understanding how cancers develop and the design of targeted therapies to these pathways offers the best hope of making a cure possible for all while reducing side effects of treatment. Our mission is to make this happen."
- Barbara A. Miller, M.D.
Chief, Division of Pediatric Hematology and Oncology and Vice Chair for Research
Four Diamonds Pediatric Cancer Research Center
Founded in 1996, the Four Diamonds Pediatric Cancer Research Center is creating new knowledge to save the lives of children with cancer. Our outstanding physicians/scientists and their teams are focused on learning more about how cancer forms, how it can be treated, and how treatments can be made to be more effective while minimizing long-term side effects of treatment.
As our research operation continues to grow, we remain committed to providing cutting edge medicine that uses the latest research findings in the care and treatment of patients.
As members of the Children's Oncology Group, our physicians and nurses are involved in the development and management of protocols used nationally to treat children with cancer.
Our Research Team is An Active Member of the Following Consortiums:
- Children's Oncology Group (COG) – a network of more than 200 leading institutions which provide state-of-the-art upfront therapies for many pediatric cancers.
- Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC) - a network of 11 leading academic medical centers, all working together to provide the collaborative and research strength needed to complete intensive phase I and phase II clinical trials of novel cancer treatments.
- Pediatric Blood and Marrow Transplant Consortium (PBMTC) - a network of clinicians and scientists engaged in scientific and educational activities related to the use of hematopoietic stem cells in the treatment of diseases of children and adolescents.
- Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) - a network of 18 universities and children's hospitals that offer a nationwide network of childhood cancer clinical trials for relapsed and refractory disease which also includes an individualized approach to treatment.
- Barbara A. Miller, M.D., Chief, Division of Pediatric Hematology and Oncology and Vice Chair for Research
- Valerie I. Brown, M.D., Director, Clinical Experimental Therapeutics Program
- Melanie Comito, M.D., Director, Neuro-oncology Program
- Simita Dandekar, M.D., Director, Pediatric Oncology Survivorship Program
- Sinisa Dovat, M.D., Ph.D., Director, Translational Research, Experimental Therapeutics Program and Developmental Therapeutics
- Robert J. Greiner, M.D., Director, Pediatric Stem Cell Transplant Program
- Lisa M. McGregor, M.D., Ph.D., Clinical Director, Pediatric Hematology and Oncology
- HG Wang, Ph.D., Director, Pediatric Molecular Oncology Program